Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs CADUET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of severe hypertension (off-label)
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Extensively metabolized in the liver via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C8, to inactive metabolites.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
>95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
8.4 L/kg (0.084 L/kg for a 70 kg adult? Please check: typical Vd is 8.4 L/kg? Actually nicardipine Vd is about 8.4 L/kg, which is large, indicating extensive tissue distribution). Correct: Vd = 8.4 L/kg (range 0.6-8.4 L/kg? Standard value is ~8.4 L/kg).
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Oral: 35% (extensive first-pass metabolism); intravenous: 100%.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
Cr Cl 30-50 m L/min: maximum IV infusion rate 8 mg/hour; Cr Cl <30 m L/min: maximum IV infusion rate 5 mg/hour. Oral: no adjustment specified but monitor closely.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
Child-Pugh Class A: start with 50% of usual dose; Class B: start with 25% of usual dose; Class C: avoid use or use extreme caution.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Limited data; for IV infusion, start at 0.5 mcg/kg/min and titrate to effect; typical range 0.5-5 mcg/kg/min. Oral: 0.5-1 mg/kg/dose three times daily (max 30 mg/dose).
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Start at lower end of dosing range; IV infusion initial rate 3 mg/hour; oral initial dose 20 mg twice daily; monitor blood pressure closely.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
None
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
Use caution in patients with coronary artery disease due to risk of increased angina or myocardial infarction,May cause hypotension, hepatic impairment, and elevated liver enzymes,May exacerbate congestive heart failure,Use with caution in patients with impaired renal function,Monitor blood pressure and heart rate during infusion
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Hypersensitivity to nicardipine or any component of the formulation,Advanced aortic stenosis (may reduce coronary perfusion),Lactation (use not recommended)
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
Grapefruit and grapefruit juice may increase nicardipine levels; avoid concurrent use. No other significant food interactions. Maintain a heart-healthy, low-sodium diet as recommended for hypertension management.
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no adequate controlled studies; first trimester: potential for teratogenic risk (class C). Second and third trimesters: may cause fetal hypoxia, metabolic acidosis, and hypotension due to maternal hypotension. Use only if benefit outweighs risk.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
NICARDIPINE is excreted in human milk. M/P ratio not reported. Limited data suggest low concentrations; however, potential for adverse effects in infant. Caution advised; consider alternative if possible.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
No specific dose adjustment guidelines for pregnancy; however, increased clearance and volume of distribution in pregnancy may necessitate higher doses. Start with lowest effective dose; titrate carefully to avoid maternal hypotension and fetal distress.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
Cardene (nicardipine) IV infusion in D5W is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It is photosensitive; protect from light. Administer via central line due to peripheral vein irritation. Titrate based on blood pressure response; onset within minutes. Use with caution in patients with severe aortic stenosis, heart failure, or hepatic impairment. Avoid in patients with advanced aortic stenosis due to risk of reducing coronary perfusion.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
This medication is given intravenously to lower blood pressure quickly.,Your blood pressure and heart rate will be monitored closely during infusion.,Report any pain, redness, or swelling at the IV site immediately.,Avoid sudden position changes to prevent dizziness or fainting.,Do not stop the infusion without medical guidance.,Inform your healthcare provider if you have liver disease, heart failure, or aortic stenosis.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs CADUET, answered by our medical review team.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.. CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and CADUET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is: Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.. The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and CADUET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no a. CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.